Clinical Trial Update: Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/Phase 2 study of a genetically engineered lymphocyte therapy for chemotherapy-resistant or refractory lymphoid cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Prolymphocytic Leukemia

Drugs mentioned

• Genetically engineered lymphocyte therapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1, Phase 2 | Status: UNKNOWN